LOS ANGELES and LA JOLLA, Calif., Oct. 5, 2012 /PRNewswire/ -- A senior research neuroscientist from The Salk Institute, Mohamedi Kagalwala PhD, has been recruited to head NeuroGeneration's new laboratories in La Jolla, California. Dr. Kagalwala, an expert on neural stem cells, will become director of the new Division of Biotherapeutics and Drug Discovery.
"I am extremely pleased to lead NeuroGeneration's new Division and expand its technology of adult neural stem cells for Parkinson's disease. It will allow us to develop personalized iPS cell therapies for degenerative brain disorders," said Dr. Kagalwala. "In addition, by investigating intrinsic neurogenesis and brain repair mechanisms, our team will be able to modify discrete molecular mechanisms during aging and neurodegenerative changes. We will then be in a better position to influence the environment, either with drugs or cellular therapies, to prevent the progression of disease and facilitate brain repair."
This new Division will complement the neural stem cell therapy studies for Parkinson's disease and other Atypical Parkinsonism led by Dr. Michel Levesque, NeuroGeneration's scientific founder.
Within the new facility providing core state of the art technologies, NeuroGeneration will expand its bioinformatic platforms to include personalized neurogenomic, analysis for drug target discovery for aging, Parkinson's disease, Stroke, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Multiple Sclerosis, Epilepsy, Depression and Schizophrenia.
NeuroGeneration is a life science company designing new cellular therapies and biological modulators for the prevention and treatment of neurodegenerative disorders. The company has completed a Phase I clinical trial for Parkinson's disease using adult-derived autologous neural stem cells. It intends to complete a Phase II study for the treatment of Parkinson's disease as soon as it receives final approval from the FDA. NeuroGeneration's Division of Biotherapeutics and Drug Discovery offers molecular products using its drug discovery platforms to target neuroprotective and endogenous repair mechanisms.
FOR MORE INFORMATION CONTACT:
Division of Biotherapeutics and Drug Discovery
3210 Merryfield Row
San Diego, CA 92121
8670 Wilshire Blvd, Suite 201
Los Angeles, CA 90211